Role of interferon anti body in predicting the response to interferon therapy in HCV patients

Journal of the Pakistan Medical Association

Volumn 57, Issue 12, 2007, Pages 581-583

  Qureshi, Huma ^d   Arif, Ambreen ^d   Ahmed, Waquaruddin ^d   Alam, Syed Ejaz ^d   Mujeeb, Syed Abdul ^a   Ul Haq, Najib ^b   Hafiz, Saleem ^c  

^a JINNAH POSTGRADUATE MEDICAL CENTRE   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

^c Mideast Medical Center   (Pakistan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON ANTIBODY; RIBAVIRIN; DIAGNOSTIC AGENT; HEPATITIS C ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; IMMUNOLOGY; PROGNOSIS;

ADULT; FEMALE; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 38349124812     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62
2. Luby SP, Qamaruddin K, Shah AA, Omair A, Pasha O, Khan AJ et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect 1997;119:349-56
3. Core Working party for Asian Pacific consensus on hepatitis B and C, a consensus statement on prevention and management of hepatitis B and C in the Asia Pacific region. J Gastroenterol hepatol 2000;15:825-41
4. Bendtzen K,, Hansen MB, Diamani M, Ross C, Svenson M. Naturally occurring autoantibodies in interleukin-1 alpha, interleukin-6, interleukin-10 and interferon-alpha. J. Interferon Res1994; 14: 157-8.
5. Avrameas S. Natural autoantibodies: from" horror autotoxicus" to "gnothi seauton". Immunol. Today 1991;12:154-9.
6. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 1999;10:413-22.
7. De Maeyer-Guignard J,De Maeyer E. Natural antibodies to interferon alpha and interferon beta are a common feature of inbred mouse strains. J immunol 1986;136:1708-11.
8. Ross C, Hansen MB, Schyberg T, Berg K. Autoantibodies to crude human leukocyte interferon (IFN),recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood dnors. Clin Exp Immunol 1990;82:57-62.
9. Caruso A, Bonfanti C, Colombrioita D, de Francesco H, De Rango C, Foeisti J et al. Natural antibodies to IFN-gamma in man and their increase dyring viral infection. J Immunol 1990;144:685-90.
10. Panem S, Check IJ, Henriksen D, Vilcek J. Antibodies to alpha interferon in a patient with systemic lupus erythematosus. J Immunol 1982;129:1-3.
11. Meager A, Vincent A, Newsom-Davis J, Willcox N. Spontaneous neutralizing antibodies to interferon-alpha and interleukin-12 in thymoma associated autoimmune disease. Lancet 1997;350:1596-7.
12. Ikeda Y, Toda G, Hashimoto N, Umeda N, Miyake K, Yamanaka M et al. Naturally occuring anti-interferon alpha 2a antibodies in patients with acute viral hepatitis. Clin Exp. Immunol 1991;85:80-4.
13. Trown PW, Kramer MJ, Dennin RA Jr, Cornell EV, Palleroni AV, Quesada J et al. Antibodies to human leukocyte interferons in cancer patients.Lancet 1983;1:81-4.
14. Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM et al. Modification of human leukocyte interferon pharmacology with monoclonal antibody.Cancer Res 1985;45:2421-4.
15. Milella M, Antonelli G, Santantonio T, Correnti M, Monno L, Mariano N et al. Neuterizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993;13:146-50.
16. Brook MG, Mc Donald JA, Karayannis P, Caruso L, Foster G, Harris JR et al. Randomised controlled trial of interferon alpha 2a (rbe)(Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection:factors that influence response.Gut 1989;30:1116-22.
17. Jacobs S, Friedman RM, Nagabhushan TL et al. Detection of serum neuterilising antibodies to interferon alpha -2b (Interon A) by means of an enzyme immunoasssy. J Interferon Res (suppl 2) 1989;9:S292.
18. Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C et al. Bioligical and clinical significance of neuterilizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994;97:4-9.
19. Antonelli G, Gianelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy. Clin Exp Immunol 1996;104:384-7.
20. Roffi L, Mels GC, Antonelli G, Bellati G. Breakthrough during recombinant alpha interferon therapy in patients with chronic hepatitis C virus infection: prevalence,etiology and management. Hepatol 1995;21:304.
21. Pachner et al. Antibodies to IFN-B in multiple sclerosis patients: measurements by a commercially available kit. Proceedings, 125th annual meeting, American Neurological Association,October 2000,Boston, MA. Abstract #230.
22. Lai YM, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW et al. Long term efficacy of Rbavarin plus interferon alpha in the treatment of chronic heaptitis C. Gatroenterology 1996;111:1307-12.
23. Berg T, Sarrazin C, Herrmann E. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
24. Zuberi SJ, Arif A. Serotyping of heaptitis C in Pakistan. J Pak Med Assoc 2002;52:218-19.